JP2018533618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533618A5 JP2018533618A5 JP2018529732A JP2018529732A JP2018533618A5 JP 2018533618 A5 JP2018533618 A5 JP 2018533618A5 JP 2018529732 A JP2018529732 A JP 2018529732A JP 2018529732 A JP2018529732 A JP 2018529732A JP 2018533618 A5 JP2018533618 A5 JP 2018533618A5
- Authority
- JP
- Japan
- Prior art keywords
- size
- less
- range
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 4
- 201000009623 Myopathy Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000004220 muscle function Effects 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 235000019482 Palm oil Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003240 coconut oil Substances 0.000 claims 1
- 235000019864 coconut oil Nutrition 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 239000002540 palm oil Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- -1 softgel Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 229930186301 urolithin Natural products 0.000 claims 1
- 0 *c(c(*)c1N)c(-c(c(C(O2)=O)c3C=C)c(*)c(N)c3O)c2c1N Chemical compound *c(c(*)c1N)c(-c(c(C(O2)=O)c3C=C)c(*)c(N)c3O)c2c1N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022144671A JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
| JP2024174863A JP2025004129A (ja) | 2015-08-28 | 2024-10-04 | ウロリチン化合物を含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1515387.7 | 2015-08-28 | ||
| GBGB1515387.7A GB201515387D0 (en) | 2015-08-28 | 2015-08-28 | Compositions |
| PCT/EP2016/070255 WO2017036992A1 (en) | 2015-08-28 | 2016-08-26 | Compositions comprising urolithin compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144671A Division JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533618A JP2018533618A (ja) | 2018-11-15 |
| JP2018533618A5 true JP2018533618A5 (https=) | 2019-10-03 |
| JP7227003B2 JP7227003B2 (ja) | 2023-02-21 |
Family
ID=54326542
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529732A Active JP7227003B2 (ja) | 2015-08-28 | 2016-08-26 | ウロリチン化合物を含む組成物 |
| JP2022144671A Pending JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
| JP2024174863A Pending JP2025004129A (ja) | 2015-08-28 | 2024-10-04 | ウロリチン化合物を含む組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144671A Pending JP2022177130A (ja) | 2015-08-28 | 2022-09-12 | ウロリチン化合物を含む組成物 |
| JP2024174863A Pending JP2025004129A (ja) | 2015-08-28 | 2024-10-04 | ウロリチン化合物を含む組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10695320B2 (https=) |
| EP (1) | EP3340977B1 (https=) |
| JP (3) | JP7227003B2 (https=) |
| KR (2) | KR102822365B1 (https=) |
| CN (1) | CN108289879A (https=) |
| AU (1) | AU2016314987B2 (https=) |
| BR (1) | BR112018003745B1 (https=) |
| CA (1) | CA2996724C (https=) |
| ES (1) | ES2936723T3 (https=) |
| GB (1) | GB201515387D0 (https=) |
| MX (1) | MX2018002543A (https=) |
| PT (1) | PT3340977T (https=) |
| RU (1) | RU2754761C2 (https=) |
| SG (1) | SG10202001793PA (https=) |
| WO (1) | WO2017036992A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6054301B2 (ja) * | 2010-12-23 | 2017-01-11 | アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ | ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法 |
| DK4233858T3 (da) | 2012-06-27 | 2025-05-12 | Amazentis Sa | Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse |
| GB201515387D0 (en) | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| US20180256538A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Method for improving mitophagy in subjects |
| CA3100335A1 (en) | 2018-05-15 | 2019-11-21 | University Of Louisville Research Foundation, Inc. | Urolithin a and derivatives thereof for use in therapy |
| GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
| CA3188397A1 (en) | 2020-09-25 | 2022-03-31 | Anupama Dattatreya | Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix |
| WO2022113693A1 (ja) * | 2020-11-30 | 2022-06-02 | 国立研究開発法人産業技術総合研究所 | 筋ジストロフィー治療剤、中心静脈栄養用組成物、筋組織の炎症抑制剤および筋ジストロフィーの抗炎症用食品組成物 |
| KR102623664B1 (ko) | 2020-12-10 | 2024-01-12 | 서울대학교산학협력단 | 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법 |
| CA3206062A1 (en) | 2021-01-27 | 2022-08-04 | Said Oumouch | Urolithin derivatives and methods of use thereof |
| EP4085906A1 (en) * | 2021-05-06 | 2022-11-09 | Universite De Bordeaux | Composition comprising ppar-modulator and an urolithin derivative and uses thereof |
| CN113813255B (zh) * | 2021-10-20 | 2023-09-01 | 山东大学 | 尿石素a及其衍生物在肿瘤免疫治疗的应用 |
| WO2023199908A1 (ja) * | 2022-04-11 | 2023-10-19 | 株式会社ダイセル | 乳化組成物の製造方法 |
| GB202219317D0 (en) * | 2022-12-20 | 2023-02-01 | Amazentis Sa | Methods for improving mitophagy in subjects |
| EP4642448A1 (en) * | 2022-12-27 | 2025-11-05 | Indian Institute of Science | A method for the treatment of epilepsy |
| GB202308224D0 (en) | 2023-06-01 | 2023-07-19 | Amazentis Sa | Formulation |
| GB202316295D0 (en) | 2023-10-24 | 2023-12-06 | Amazentis Sa | Composition |
| EP4555997A1 (en) * | 2023-11-15 | 2025-05-21 | Science4Beauty Sp. z o.o. | Water-soluble composition comprising urolithin |
| GB202319994D0 (en) | 2023-12-22 | 2024-02-07 | Amazentis Sa | Compositions for use |
| KR20250158913A (ko) | 2024-04-30 | 2025-11-07 | 주식회사 파이안바이오테크놀로지 | 유로리틴을 함유하는 탈모완화제와 모발성장촉진제 |
| WO2025252771A1 (en) | 2024-06-03 | 2025-12-11 | Amazentis Sa | Urolithin combinations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| BR9708248A (pt) | 1996-03-26 | 1999-07-27 | Lilly Co Eli | Benzotiofenos formulações contendo os mesmos e metódos |
| WO1999053941A1 (fr) * | 1998-04-15 | 1999-10-28 | Shionogi & Co., Ltd. | Preparations orales contenant des derives de trh |
| CA2363123C (en) | 1999-02-22 | 2011-09-06 | Kenneth Iain Cumming | Solid oral dosage form containing an enhancer |
| US6623734B2 (en) * | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
| US20050282781A1 (en) | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
| WO2006035900A1 (ja) | 2004-09-29 | 2006-04-06 | San-Ei Gen F.F.I., Inc. | コエンザイムｑ１０含有乳化組成物 |
| US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| US8894993B2 (en) * | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
| EP2145904A1 (de) | 2008-07-18 | 2010-01-20 | Basf Se | Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen |
| CN102176900B (zh) | 2008-09-17 | 2017-09-26 | 克艾思马有限公司 | 药物组合物和相关的给药方法 |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| PT2547205T (pt) | 2010-03-19 | 2024-05-27 | 1Globe Biomedical Co Ltd | Novos métodos para atingir células estaminais cancerígenas |
| EP2550092B1 (de) | 2010-03-22 | 2018-08-15 | Instillo GmbH | Verfahren zur herstellung von mikro- oder nanopartikeln |
| WO2011131943A2 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical compositions |
| US20140107100A1 (en) | 2010-11-24 | 2014-04-17 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture |
| JP2012111712A (ja) | 2010-11-25 | 2012-06-14 | Toyo Capsule Kk | 油性ビタミンｃ経口投与用組成物 |
| JP6054301B2 (ja) * | 2010-12-23 | 2017-01-11 | アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ | ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法 |
| EP2661273A4 (en) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION |
| CA2826884A1 (en) * | 2012-09-14 | 2014-03-14 | Natreon, Inc. | Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit |
| GB201323008D0 (en) * | 2013-12-24 | 2014-02-12 | Amazentis As | Compounds and uses thereof |
| GB201515387D0 (en) | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
-
2015
- 2015-08-28 GB GBGB1515387.7A patent/GB201515387D0/en not_active Ceased
-
2016
- 2016-08-26 CA CA2996724A patent/CA2996724C/en active Active
- 2016-08-26 KR KR1020247012842A patent/KR102822365B1/ko active Active
- 2016-08-26 MX MX2018002543A patent/MX2018002543A/es unknown
- 2016-08-26 WO PCT/EP2016/070255 patent/WO2017036992A1/en not_active Ceased
- 2016-08-26 KR KR1020187007291A patent/KR102660005B1/ko active Active
- 2016-08-26 RU RU2018108136A patent/RU2754761C2/ru active
- 2016-08-26 EP EP16757263.5A patent/EP3340977B1/en active Active
- 2016-08-26 AU AU2016314987A patent/AU2016314987B2/en active Active
- 2016-08-26 US US15/757,293 patent/US10695320B2/en active Active
- 2016-08-26 CN CN201680050456.6A patent/CN108289879A/zh active Pending
- 2016-08-26 BR BR112018003745-1A patent/BR112018003745B1/pt active IP Right Grant
- 2016-08-26 PT PT167572635T patent/PT3340977T/pt unknown
- 2016-08-26 JP JP2018529732A patent/JP7227003B2/ja active Active
- 2016-08-26 SG SG10202001793PA patent/SG10202001793PA/en unknown
- 2016-08-26 ES ES16757263T patent/ES2936723T3/es active Active
-
2020
- 2020-06-15 US US16/901,182 patent/US11337957B2/en active Active
-
2022
- 2022-05-05 US US17/737,605 patent/US11925616B2/en active Active
- 2022-09-12 JP JP2022144671A patent/JP2022177130A/ja active Pending
-
2024
- 2024-01-19 US US18/417,794 patent/US20240148690A1/en not_active Abandoned
- 2024-10-04 JP JP2024174863A patent/JP2025004129A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533618A5 (https=) | ||
| RU2018108136A (ru) | Композиции, содержащие уролитины | |
| BR112013019732B1 (pt) | Composição farmacêutica e seu uso no tratamento de doenças cardiovasculares | |
| JP2015531344A5 (https=) | ||
| BR112017017310B1 (pt) | Composições lipídicas e suplemento alimentar ou nutricional, alimento médico ou funcional e veículo de liberação oral compreendendo as ditas composições | |
| BR112013025088B1 (pt) | Composições farmacêuticas orais líquidas e método de tratar ou impedir uma doença neurodegenerativa | |
| JP2014517028A5 (https=) | ||
| RU2020118504A (ru) | Двойные эмульсии | |
| JP2014530204A5 (https=) | ||
| JP6519087B2 (ja) | カロチノイド化合物の異性体比の維持のための新規方法 | |
| FR3050639B1 (fr) | Nouveau complement alimentaire et medicament | |
| TWI669062B (zh) | Composition containing high amounts of sesamin | |
| JP7157743B2 (ja) | ケトン体生成促進剤 | |
| JP6552526B2 (ja) | ω−３多価不飽和脂肪酸及びレスベラトロールを含む経口投与用均質処方物 | |
| KR102671055B1 (ko) | 분리대두단백 및 커큐민을 포함하는 운동수행능력 향상용 조성물 | |
| JP6519875B2 (ja) | 改良された魚油ベースのオメガ３補助食品 | |
| CN106456587B (zh) | 含有欧米茄-3和白藜芦醇的固体制剂 | |
| JP2017155025A (ja) | 脂質組成物 | |
| JP5991836B2 (ja) | ギンコライドと魚介油を含有する組成物 | |
| HK1257500B (en) | Compositions comprising urolithin compounds | |
| WO2015163091A1 (ja) | 不飽和脂肪酸の吸収促進剤 |